<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913090</url>
  </required_header>
  <id_info>
    <org_study_id>5610-1-001</org_study_id>
    <nct_id>NCT04913090</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects</brief_title>
  <official_title>A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) of XZP-5610 Tablets Following Single- and Multiple-ascending Doses (SAD/MAD) and Food Effects in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanzhu Biopharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanzhu Biopharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will consist of 3 parts: Part A - Single Ascending Dose (SAD) phase, Part B -&#xD;
      multiple ascending dose (MAD) phase, and Part C - Food Effect (FE) phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A and Part B studies were designed as single-center, randomized, double-blind,&#xD;
      placebo-controlled, dose-escalation trials to assess the safety, tolerability,&#xD;
      pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single and multiple oral doses of&#xD;
      XZP-5610 tablets in healthy adult subjects, and exploring preliminary food effects&#xD;
      (non-high-fat meals) in the Part B study. Part C is a single-center, randomized, open, 2×2&#xD;
      crossover design designed to assess the foodeffects on PK of a single oral dose of XZP-5610&#xD;
      tablets in healthy adult subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2021</start_date>
  <completion_date type="Anticipated">March 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of adverse events for XZP-5610 versus placebo</measure>
    <time_frame>From drug administration to study completion. Single dose：15 days , Multi dose: 42 days，Food Effect: 11 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>Part A-experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose (SAD) phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single Ascending Dose (SAD) phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B-experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple ascending dose (MAD) phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>multiple ascending dose (MAD) phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C1-experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Food Effect (FE) phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C2-experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Food Effect (FE) phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-5610 Tablet (for Part A)</intervention_name>
    <description>Tablet(s) administered orally once daily for 1 Day</description>
    <arm_group_label>Part A-experimental</arm_group_label>
    <other_name>5610</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match XZP-5610 Tablet (for Part A)</intervention_name>
    <description>Tablet(s) administered orally once daily for 1 Day</description>
    <arm_group_label>Part A-placebo</arm_group_label>
    <other_name>5610 Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-5610 Tablet (for Part B)</intervention_name>
    <description>Tablet(s) administered orally once daily for 14 Days</description>
    <arm_group_label>Part B-experimental</arm_group_label>
    <other_name>5610</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match XZP-5610 Tablet (for Part B)</intervention_name>
    <description>Tablet(s) administered orally once daily for 14 Days</description>
    <arm_group_label>Part B-placebo</arm_group_label>
    <other_name>5610 Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-5610 Tablet （for &quot;Part C1&quot;）</intervention_name>
    <description>Tablet(s) administered fasted orally once daily for 1 Day</description>
    <arm_group_label>Part C1-experimental</arm_group_label>
    <arm_group_label>Part C2-experimental</arm_group_label>
    <other_name>5610</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-5610 Tablet for &quot;Part C2&quot;</intervention_name>
    <description>Tablet(s) administered after a high-fat meal orally once daily for 1 Day</description>
    <arm_group_label>Part C1-experimental</arm_group_label>
    <arm_group_label>Part C2-experimental</arm_group_label>
    <other_name>5610</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult males or females aged 18 to 60 years (inclusive).&#xD;
&#xD;
          2. Body weight ≥ 50 kg for males and ≥ 45 kg for females; body mass index (BMI) in the&#xD;
             range 19.0-28.0 kg/m2 for the non-obese group and in the range of 28.1 -35.0 kg/ 2 for&#xD;
             the obese group (inclusive, BMI=weight/height2).&#xD;
&#xD;
          3. No plans to have children within the last 6 months, no plans to donate sperm/egg, and&#xD;
             willing to use effective contraception within 6 months after the end of dosing&#xD;
&#xD;
          4. No clinically significant vital signs, physical examination, laboratory tests, or ECG&#xD;
             or chest radiograph findings.&#xD;
&#xD;
          5. Subjects understand and comply with the study procedures, voluntarily participate, and&#xD;
             sign an Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of severe systemic diseases such as endocrine, gastrointestinal,&#xD;
             cardiovascular, hematological, hepatic, immunological, renal, respiratory,&#xD;
             genitourinary or major neurological (including stroke and chronic epilepsy)&#xD;
             abnormalities.&#xD;
&#xD;
          2. History of clinically significant ECG abnormalities or family history of long QT&#xD;
             syndrome (grandparents, parents and siblings)&#xD;
&#xD;
             Part A:&#xD;
&#xD;
             Any of the following was regarded as a criterion for exclusion:&#xD;
&#xD;
               1. Confirmation of QTcF ≥ 450 ms by repeated measurements;&#xD;
&#xD;
               2. Confirmation of QRS duration &gt; 120 ms by repeated measurements;&#xD;
&#xD;
               3. Confirmation of PR interval &gt; 200 ms by repeated measurements;&#xD;
&#xD;
               4. Findings that lead to difficulties in QTc measurement or difficult interpretation&#xD;
                  of QTc data;&#xD;
&#xD;
               5. History of other risk factors for Torsades de Pointes tachycardia (e.g., heart&#xD;
                  failure, hypokalemia, family history of long QT syndrome);&#xD;
&#xD;
               6. Presence of uncorrected hypokalemia or hypomagnesemia.&#xD;
&#xD;
             Parts B and C:&#xD;
&#xD;
             Any of the following was regarded as a criterion for exclusion:&#xD;
&#xD;
               1. Family history of long QT syndrome (grandparents, parents and siblings);&#xD;
&#xD;
               2. Resting QTcF ≥ 450 ms (males) or ≥ 460 ms (females) during the screening or&#xD;
                  baseline period.&#xD;
&#xD;
          3. Subjects with a known or suspected history of allergy to the test drug or its adjuvant&#xD;
             components, or a history of clinically significant severe allergy (e.g., food, drug,&#xD;
             latex allergy), or a history of atopic allergic disease (asthma, urticaria, eczematous&#xD;
             dermatitis)&#xD;
&#xD;
          4. History of dysphagia or any gastrointestinal disorder affecting drug absorption at&#xD;
             screening, including history of frequent nausea or vomiting of any etiology, history&#xD;
             of irregular gastrointestinal motility such as habitual diarrhea, constipation or&#xD;
             bowel pre-excitation syndrome, or history of major gastrointestinal surgery (e.g.,&#xD;
             gastrectomy, gastrointestinal anastomosis, bowel resection, gastric bypass, gastric&#xD;
             division, or gastric banding)&#xD;
&#xD;
          5. History of pancreatic injury or pancreatitis at screening, or significantly elevated&#xD;
             blood amylase (&gt; 1.5 x ULN)&#xD;
&#xD;
          6. History of urinary tract obstruction or presence of urinary voiding difficulties at&#xD;
             screening.&#xD;
&#xD;
          7. History of cancer (malignancy) at the time of screening.&#xD;
&#xD;
          8. Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B&#xD;
             surface antigen (HBsAg), hepatitis C virus (HCV) antibody or syphilis antibody&#xD;
&#xD;
          9. History of significant drug abuse within 12 months prior to screening or positive&#xD;
             urine drug screening&#xD;
&#xD;
         10. Regular alcohol consumption within 3 months prior to screening, consuming more than 3&#xD;
             alcoholic drinks per day (one drink is approximately equal to: beer 354 mL/12 ounces,&#xD;
             wine 118 mL/4 ounces, or distilled spirits 29.5 mL/1 ounce), or evidence of alcohol&#xD;
             abuse and excessive consumption as evidenced by alcohol breath test at screening&#xD;
             (subjects who consume 4 alcoholic beverages per day may be enrolled at the&#xD;
             investigator's (enrollment is at the discretion of the investigator).&#xD;
&#xD;
         11. History of smoking within 3 months prior to screening, or a positive urine nicotine&#xD;
             test at screening, or who cannot give up smoking throughout the study period&#xD;
&#xD;
         12. Excessive daily intake of coffee, tea, cola, energy drinks, or other caffeinated&#xD;
             beverages within 3 months prior to screening, with excess defined as more than 6&#xD;
             servings (one servingis approximately equal to 120 mg of caffeine).&#xD;
&#xD;
         13. Major surgery, or donation or loss of blood over 400 mL within 3 months prior to&#xD;
             administration.&#xD;
&#xD;
         14. Participation in other clinical trials and treatment with investigational&#xD;
             productinvestigational product within 3 months prior to administration.&#xD;
&#xD;
         15. Taken any prescription, over-the-counter, nutraceutical, herbal or proprietary Chinese&#xD;
             medicine within 4 weeks prior to administration (or less than 5 half-lives of the drug&#xD;
             from the start of the trial).&#xD;
&#xD;
         16. Women who are pregnant or breastfeeding, or of childbearing potential who are not&#xD;
             using effective non-hormonal contraception (intrauterine device (IUD), barrier method&#xD;
             with spermicide, or surgical sterilization, etc.) or are unwilling to continue using&#xD;
             these methods during the trial until 6 months after discontinuation; men of&#xD;
             childbearing potential who are unwilling to use physical methods of contraception&#xD;
             during the trial until 6 months after discontinuation.&#xD;
&#xD;
         17. Systolic blood pressure ≥ 140 mmHg or &lt; 90 mmHg, and/or diastolic blood pressure ≥ 90&#xD;
             mmHg or &lt; 50 mmHg at screening or prior to dosing&#xD;
&#xD;
         18. Heart rate &lt; 50 or &gt; 100 beats/min at screening or prior to dosing.&#xD;
&#xD;
         19. The estimated glomerular filtration rate (eGFR) &lt; 90 ml/min/ 1.73m2 at screening based&#xD;
             on the Modification of Diet in Renal Disease Study (MDRD) formula (see Appendix 1 for&#xD;
             calculation formula).&#xD;
&#xD;
         20. At screening, the liver function tests of non-obese group showed any measure of&#xD;
             aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase&#xD;
             (ALP), or total bilirubin&gt; upper limit of normal (ULN); the liver function tests of&#xD;
             obese group showed AST, ALT, or ALP&gt; 1.5 × ULN, or total bilirubin&gt; ULN.&#xD;
&#xD;
         21. Fasting triglycerides &gt; 200 mg/dL (2.27 mmol/L) at screening.&#xD;
&#xD;
         22. Fasting glucose &gt; 5.6 mmol/L in the non-obese group and &gt; 6.1 mmol/L or glycosylated&#xD;
             hemoglobin (HbA1c) ≥ 6.5% in the obese group at screening.&#xD;
&#xD;
         23. Those who could not tolerate blood sample collection.&#xD;
&#xD;
         24. Subjects who are deemed by the investigator to be unsuitable for participation in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongyang Liu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Chen</last_name>
    <phone>+86-13910591245</phone>
    <email>chenying@xuanzhubio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongyang Liu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

